

























Aging is defined as a decline caused by accumulation of 
all sorts of damage, in particular, molecular damage.   
This statement seemed so obvious that it was not 
questioned. Yet several lines of evidence rule out 
molecular damage as a cause of aging [1-15].  Yes, of 
course, molecular damage accumulates over time. But 
this accumulation is not sufficient to cause organismal 
death. Eventually it would. But the organism does not 
live long enough, because another cause terminates life 
first [8]. This cause is aging, a continuation of 
developmental growth.  Definitely, developmental 
growth is not driven by accumulation of molecular 
damage, although molecular damage accumulates. 
Similarly, aging is not driven by damage. 
 
Growth is stimulated in part by mitogen- and nutrient-
sensing (and other) signaling pathways such as mTOR 
[16-35].  Aging, “an aimless continuation of develop-
mental program”, is driven by the same signaling 
pathways including mTOR [8, 14, 24].  Aging in turn 
causes damage: not molecular damage but non-random 
organ damage (stroke, infarction, renal failure and so 
on) and death [13]. Seemingly, one objection to this 
concept is that cancer is caused by molecular damage.  
And cancer is often a cause of death in mammals. So 
how may one claim that damage does not drive aging, if 
it is involved in cancer. Let us discuss this. 
 
 























Damage in cancer  
 
Damage causes activate oncogenes and de-activate 
tumor suppressors due to genetic mutations, epigenetic 
alterations and microRNAs dysregulation [36-57]. Even 
according to alternative theories, cancer is caused by 
damage too [58]. So damage is involved in cancer. 
There are some exceptions, mostly related to embryonic 
cells. Also, in theory, extra-genetic alterations such as 
stable activation of oncogenic pathways via positive 
feedback loops can contribute to malignant phenotype 
[59]. Finally, positive feedback loops could be 
established between cancer and normal cells [59-61]. 
But in general molecular damage is a key factor in 
cancer origin. In agreement, cancer is associated with 
genetic instability [59, 62-69]. 
 
Not decline but robustness  
 
Due to genetic instability, cancer cells accumulate high 
levels of unrepaired damage, resulting in genomic 
mutations and epigenetic alterations as well as 
aneuploidy [36-49, 70-80]. Despite of accumulation of 
damage, cancer is neither decline nor ‘wear and tear’. 
Cancer cells are robust and aggressive.  Cancer cells 
damage organs, thus killing organism. If cancer cells 
with all damage are so robust, then how possibly aging 
of normal cells could be “a decline due to accumulation 
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Cancer is associated with cellular immortality [38, 81-
88]. Not only cancer cells can become cell lines but also 
they can become free-living organisms [89-96]. Such 
free-living cancer cells spread from one animal to 
another.  Thus, venereal sarcoma in dogs spread as 
unicellular mammalian organisms for several millennia, 
once originated from a single cancer cell [89-96]. Thus 
accumulation of damage is associated with cellular 
immortality. 
 
Damage is not sufficient to cause cancer 
 
However, molecular damage is not sufficient either to 
cause cancer or to hurt organism. This damage is 
multiplied billions of times via cell replication.  Also, 
cells with random mutations undergo non-random 
selection (Figure 1).  
 
Multiplication and selection 
 
A 1 cm tumor contains 10
9 (1 billion) cells. Therefore, 
































multiplied. Cells undergo clonal selection, analogous to 
Darwinian selection [70, 97-100]. Importantly, most 
mutations are so called “passenger” mutations that 
remain random and useless [72, 79, 80, 101]. But 




Oncogenic mutations occur randomly. Cancer arises 
when cellular microenvironment favors oncogenic 
mutations, creating selective advantage to cells bearing 
oncogenic mutations.  For example, carcinogens not 
only damage DNA but also cytostatic to normal cells, 
thus favoring selection of oncogenic mutations that 
render cells resistant to cytostatic/toxic carcinogens 
[102, 103]. This is especially apparent with non-
damaging carcinogens such as phorbol esters [104]. 
Cancer therapy can select for additional oncogenic 
mutations (such as loss of p53), rendering cancer cells 
not only drug resistant but also increasingly oncogenic 
[102, 103, 105-108]. Inflammation and chronic 
infections also favor cancer [109-121]. And the aging 
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Organismal aging is the most important risk factor in 
common cancers such as prostate, breast, colon, gastric, 
lung, pancreatic, skin, brain, thyroid (and so on) cancers 
as well as melanomas and certain leukemias. Calorie 
restriction [129-137] and rapamycin [138-141], which 
decelerate aging, also postpone cancer. Why does aging 
favors cancer? One explanation is that aging stromal 
cells secrete factors that promote growth of pre-cancer 
cells [122, 123, 142-144] and aging is associated with 
pro-inflammation that favors cancer growth [145-147]. 
The pro-inflammatory NF-kB pathway is involved in 
both DNA damage response (DDR), cancer and aging 
[60, 147-156]. 
 
  One additional explanation is that chronic 
overactivation of mTOR renders normal cells 
irresponsive to growth factors [157]. (In fact, 
mTOR/S6K renders cells resistant to insulin and growth 
factors [158, 159]). Then, cancer cells, which are 
growth signal- independent, acquire selective 
advantage. In theory, by restoring responsiveness of 
normal cells to mitogenic signals, treatment with 
rapamycin can eliminate selective advantage for cancer 
cells. It was predicted that rapamycin can restore 
responsiveness of aging cells [157]. In fact, mTOR may 
cause exhaustion of the proliferative potential of stem 
cells and, in some studies, rapamycin improved the 
responsiveness of aging stem cells and immune cells 
[160-163]. As an example, activation of mTOR 
promoted leukemia-initiated cells, while depleting 
normal hematopoietic stem cell. Rapamycin not only 
depleted leukaemia-initiating cells but also restored 
normal stem cell function  [160,  164]. Thus decreased 
proliferative potential of normal cells is associated with 
selective advantage to cancer cells. 
 
 
Non-random activation of the PI3K/mTOR pathway 
 
The PI3K/mTOR pathway is universally involved in 
cancer [37, 165-180].  It is activated by mutations in 
PI3K, Ras, Raf, non-receptor and growth factor receptor 
kinases and autocrine growth factors [165, 177, 181, 
182]. Also, inactivation of tumor suppressors such as 
PTEN, AMPK, TSC2, LKB1, NF1 causes activation of 
this pathway [160, 169, 183-191]. In addition, the 
hypertrophic effect is often achieved via activation of 
downstream mTOR targets, translation factors [178]. 
Finally, p53, which is lost in cancer, is also a suppressor 
of the mTOR pathway [192-201]. Therefore, it can 
suppress conversion of cell cycle arrest to senescence 
[198-204]. In turn, the GF/PI3K/Akt/mTOR pathway 
drives cellular mass growth, hypersecrtory phenotype, 
HIF-1 expression, angiogenic phenotype, high levels of 
glycolysis and biosyntesis (metabolic switch) and 
apoptosis avoidance  [16-35, 205-208]. In other words, 
it is involved in most of hallmarks of cancer [38, 88], 
with a notable exception of loss of cell cycle control.  
On the other hand, the mTOR pathway is involved in 
senescent phenotype.  Therefore, the second alteration 
in cancer is deactivation of cell cycle checkpoints. Thus 
cancer cells can be viewed as cycling senescent cells. 
 
Avoiding cell cycle arrest 
 
In order to proliferate, cell with TOR-activating 
oncogenes must disable cell cycle control.  Inactivation 
of tumor suppressors such p53, Rb, p16 and activation 
of c-myc, cyclins D and E, all disable cell cycle control, 
allowing “pro-senescent” cancer cell to proliferate [209-
216].  Still, acute DNA damage, anticancer drugs and 
induction of p21 or p16 cause cell cycle arrest. Arrested 
cancer cells rapidly become senescent (geroconversion), 
revealing their pro-senescent phenotype.    
 
Oncogenic transformation and gerogenic conversion 
 
There are non-mutually exclusive ways to depict 
oncogenic transformation, as complementary activation/ 
disabling of signaling pathways [88, 217-225].  Here to 
compare cancer with aging, I view oncogenic 
transformation as (a) activation of growth-promoting 
pathways such as mTOR and (b) loss of cell cycle 
control. Growth promoting pathways can drive either 
growth or aging, whereas avoidance of cell cycle arrest 
precludes aging (Fig. 1). In quiescent cells, activation of 
growth-promoting pathways (such as mTOR) converts 
quiescence into senescence, a process named gerogenic 
conversion or geroconversion [226, 227]. In 
proliferating cells, mTOR is fully activated.  Induction 
of cell cycle arrest, without inhibition of mTOR causes 
gerogenic conversion too. When cell cycle is arrested, 
growth-promoting pathways drive hypertrophy and 
aging instead of growth. The difference between 
quiescence and senescence was recently discussed in 
detail [227]. Cellular hyper-functions and feedback 
signal resistance are manifestations of cellular 
senescence/aging that lead to age-related diseases [227]. 
These hallmarks result from excessive activation of 
signaling pathways not from accumulation of damage.   
 
Why aging is not caused by accumulation of damage 
 
To harbor the active mTOR pathway, cancer cells 
undergo multiple rounds of selection. In other words, 
numerous random mutations are selected for non-random 
activation of mTOR.  In contrast it is resting non-dividing 
cells such as liver, muscle, fat, connective tissue, neurons 
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only levels of molecular damage are low in normal cells, 
but also there is no amplification and selection.   So 
random damage hardly can cause non-random activation 
of mTOR. Noteworthy, calorie restriction (CR) inhibits 
mTOR. Even short-term CR suppresses cellular 
senescence in the organism [228, 229]. 
 
Extragenetic activation of mTOR in aging 
 
mTOR pathway is activated by growth factors, 
hormones, mitogens, pro-inflammatory cytokines and 
other secretory molecules and nutrients. Cells can 
overactivate each other, via positive feedback loops. For 
example in the liver and fat, hyper-active mTOR causes 
insulin-resistance, which in turn leads to activation 
mTOR in beta-cells, which produce insulin. Insulin 
further activates mTOR in the liver and fat. 
 
DNA damage response (DDR) and aging 
 
In proliferating cells, mTOR is fully activated.  Acute 
DNA damage induces DDR and cell cycle arrest. If 
mTOR is still active, such cells undergo geroconversion. 
Rapamycin and other inhibitors of the mTOR pathway 
decelerate geroconversion [198, 200, 206, 226, 230-
236]). This is how accelerated senescence is usually 
induced in proliferating cells (in cell culture). However, 
in quiescent cells with inactive mTOR, DNA damage 
does not induce sensecence, whereas activation of mTOR 
does [226, 237].  
 
In oncogene-induced senescence (OIS), DDR causes cell 
cycle arrest, leading to senescence [238-245]. Note-
worthy, most oncogenes that induce senescence (Ras, 
Raf, MEK, Akt  and so on) activate the mTOR pathway. 
We can call them TOR-activating oncogenes or 
gerogenes  [14], because they are  involved in aging from 
cells to organisms  [14,  246,  247]. Loss of PTEN also 
activates the mTOR pathway, causing senescence  [243].  
In OIS, oncogenes induce cell cycle arrest but not 
necessary DNA damage or even DDR  [248,  243,  249]. 
Furthermore, atypical DDR can occur without DNA 
damage (pseudo-DDR) [231, 236, 250-256]. DDR path-
ways and the mTOR pathway are interconnected [257-
260]. And it seems that pseudo-DDR and DDR are 
markers of cellular hyper-activation associated with sene-
scence [145] and can be blocked by rapamycin  [231]. 
 
Cancer prevention and therapy 
 
  Prevention of DNA damage can decrease cancer 
incidence.  For example, non-smoking prevents 
smoking-induced cancer.  Also, cancer can be prevented 
by decelerating the aging process by calorie restriction 
and rapamycin. Both calorie restriction and rapamycin 
delay cancer. Although rapalogs can directly affect 
cancer cells, rapalogs are only modestly effective as 
anti-cancer therapy [168, 261, 262], compared with 
their dramatic preventive effects. In any case, cancer 
can be prevented without decreasing levels of molecular 
damage. Furthermore, DNA damaging drugs are 
cornerstone of cancer therapy.  And these drugs are also 
carcinogens, because anti-cancer and carcinogenic 




Although molecular damage is typically necessary for 
cancer initiation, this damage limits life span not 
because of cellular decline but because of cellular 
robustness. Damage undergoes multiplication and 
selection. Aging by itself is a selective force that favors 
cancer probably because aging cells are signal resistant, 
thus providing selective advantage to cells that by-pass 
the need in mitogenic signals. In addition to non-
random selection for oncogenic mutations, cancer cells 
accumulate even higher levels of random “passenger” 
mutations. Despite that cancer cells are robust. It must 
be expected that a lower rate of DNA damage in normal 
cells cannot cause cellular decline.  Yes, molecular 
damage accumulates but is not a driving force for aging. 
Aging would occur in the absence of any molecular 
damage. On the other hand, yes, molecular damage is 
involved in something like cancer that can limit lifespan 
in mammals to some extend. Noteworthy, worms and 
flies do not die from cancer. Still they undergo 
PI3K/TOR-dependent aging [263-269].   
 
As already discussed, if quasi-programmed TOR-driven 
aging would be eliminated, thus extending lifespan, 
then accumulation of molecular damage would become 
life-limiting [10].  In any case, in mammals, cellular 
aging (characterized by cellular overactivation, 
hyperfunction and secondary signal resistance) can 
cause diseases, which lead to organ damage. And 
cancer, an age-related disease, is not an exception: it 
kills not because cancer cells fail due to decline but 
because these cells damage organs. Perhaps, cancer is 
not the only one damage-related disease among aging-
dependent conditions. But a subtle interference of 
molecular damage with TOR-driven aging will be a 
topic for another article, which will discuss the intricate 
relationship between non-random organ damage and 
random molecular damage.   
 
CONFLICT OF INTERESTS STATEMENT 
 
The author of this manuscript has no conflict of interest 
to declare. 
   
www.impactaging.com                1133                                  AGING,  December 2011, Vol.3 No.12REFERENCES 
 
1. Doonan R, McElwee JJ, Matthijssens F, Walker GA, Houthoofd K, 




2.  Gems  D,  Doonan  R.  Antioxidant  defense  and  aging  in  C. 










Hekimi  S.  Decreased  energy  metabolism  extends  life  span  in 
Caenorhabditis  elegans  without  reducing  oxidative  damage. 
Genetics. 2010; 185: 559‐571. 
6.  Speakman  JR,  Selman  C.  The  free‐radical  damage  theory: 
Accumulating evidence against a simple link of oxidative stress 
to ageing and lifespan. Bioessays. 2011; 33: 255‐259. 








10.  Blagosklonny  MV.  Program‐like  aging  and  mitochondria: 








14.  Blagosklonny  MV.  Revisiting  the  antagonistic  pleiotropy 













20.  Tee  AR,  Blenis  J.  mTOR,  translational  control  and  human 
disease. Semin Cell Dev Biol. 2005; 16: 29‐37. 
21.  Dann  SG,  Selvaraj  A,  Thomas  G.  mTOR  Complex1‐S6K1 










































40.  Lukas  J,  Lukas  C,  Bartek  J.  More  than  just  a  focus:  The 
chromatin  response  to  DNA  damage  and  its  role  in  genome 
integrity maintenance. Nat Cell Biol. 2011; 13: 1161‐1169. 








44.  Timp  W,  Levchenko  A,  Feinberg  AP.  A  new  link  between 
epigenetic  progenitor  lesions  in  cancer  and  the  dynamics  of 
signal transduction. Cell Cycle. 2009; 8: 383‐390. 
45.  Johnson  SM,  Grosshans  H,  Shingara  J,  Byrom  M,  Jarvis  R, 
Cheng  A,  Labourier  E,  Reinert  KL,  Brown  D,  Slack  FJ.  RAS  is 
regulated by the let‐7 microRNA family. Cell. 2005; 120: 635‐647. 
46.  Calin  GA,  Ferracin  M,  Cimmino  A,  Di  Leva  G,  Shimizu  M, 









48.  Burdach  S,  Plehm  S,  Unland  R,  Dirksen  U,  Borkhardt  A, 
Staege MS, Muller‐Tidow C, Richter GH. Epigenetic maintenance 

















55.  Pekarsky  Y,  Croce  CM.  Is  miR‐29  an  oncogene  or  tumor 
suppressor in CLL? Oncotarget. 2010; 1: 224‐227. 
56.  Valastyan  S,  Weinberg  RA.  miR‐31:  a  crucial  overseer  of 
tumor metastasis and other emerging roles. Cell Cycle. 2010; 9: 
2124‐2129. 







60.  Martinez‐Outschoorn  UE,  Trimmer  C,  Lin  Z,  Whitaker‐
Menezes D, Chiavarina B, Zhou J, Wang C, Pavlides S, Martinez‐
Cantarin MP, Capozza F, Witkiewicz AK, Flomenberg N, Howell A, 
Pestell  RG,  Caro  J,  Lisanti  MP  et  al.  Autophagy  in  cancer 

















Yaguchi  T,  Wadhwa  R  et  al.  Cell  cycle  checkpoint  defects 
contribute  to  genomic  instability  in  PTEN  deficient  cells 
independent of DNA DSB repair. Cell Cycle. 2009; 8: 2198‐2210. 


















Ustyanksky  V,  Nikolskaya  T,  Nikolsky  Y  et  al.  The  genomic 
landscapes  of  human  breast  and  colorectal  cancers.  Science. 
2007; 318: 1108‐1113. 
72. Carter H, Chen S, Isik L, Tyekucheva S, Velculescu VE, Kinzler 
KW,  Vogelstein  B,  Karchin  R.  Cancer‐specific  high‐throughput 
annotation  of  somatic  mutations:  computational  prediction  of 
driver missense mutations. Cancer Res. 2009; 69: 6660‐6667. 
73.  Zhao  L,  Vogt  PK.  Hot‐spot  mutations  in  p110alpha  of 






75.  McClelland  SE,  Burrell  RA,  Swanton  C.  Chromosomal 
instability: a composite phenotype that influences sensitivity to 
chemotherapy. Cell Cycle. 2009; 8: 3262‐3266. 





arise  from  a  pair  of  driver  mutations  uncommonly  seen  as 
singlet mutations: one‐third of doublets occur at five pairs of 
amino acids. Oncogene. 2008; 27: 4336‐4343. 
78.  Torkamani  A,  Schork  NJ.  Prediction  of  cancer  driver 
mutations in protein kinases. Cancer Res. 2008; 68: 1675‐1682. 
79.  Loriaux  MM,  Levine  RL,  Tyner  JW,  Frohling  S,  Scholl  C, 
Stoffregen EP, Wernig G, Erickson H, Eide CA, Berger R, Bernard 
OA, Griffin JD, Stone RM, Lee B, Meyerson M, Heinrich MC et al. 










chromosome  instability  is  arrested  in  immortal  cells  which 
express telomerase activity. Embo J. 1992; 11: 1921‐1929. 
   
www.impactaging.com                  1135                                  AGING, December 2011, Vol.3 No.1282. Harley CB, Kim NW, Prowse KR, Weinrich SL, Hirsch KS, West 





vitro  telomerase  activity,  telomere  maintenance,  and  cellular 
immortalization.  Proc  Natl  Acad  Sci  U  S  A.  1998;  95:  14723‐
14728. 









87.  Bazarov  AV,  Hines  WC,  Mukhopadhyay  R,  Beliveau  A, 
Melodyev S, Zaslavsky Y, Yaswen P. Telomerase activation by c‐
Myc  in  human  mammary  epithelial  cells  requires  additional 
genomic changes. Cell Cycle. 2009; 8: 3373‐3378. 












93.  Siddle  HV,  Kreiss  A,  Eldridge  MD,  Noonan  E,  Clarke  CJ, 
Pyecroft S, Woods GM, Belov K. Transmission of a fatal clonal 
tumor  by  biting  occurs  due  to  depleted  MHC  diversity  in  a 
threatened  carnivorous  marsupial.  Proc  Natl  Acad  Sci  U  S  A. 
2007; 104: 16221‐16226. 
94.  McAloose  D,  Newton  AL.  Wildlife  cancer:  a  conservation 
perspective. Nat Rev Cancer. 2009; 9: 517‐526. 
95.  Murchison  EP.  Clonally  transmissible  cancers  in  dogs  and 
Tasmanian devils. Oncogene. 2008; 27 Suppl 2: S19‐30. 
96. Murchison  EP, Tovar C,  Hsu A, Bender HS, Kheradpour P, 
Rebbeck  CA,  Obendorf  D,  Conlan  C,  Bahlo  M,  Blizzard  CA, 
Pyecroft  S,  Kreiss  A,  Kellis  M,  Stark  A,  Harkins  TT,  Marshall 






98.  Cahill  DP,  Kinzler  KW,  Vogelstein  B,  Lengauer  C.  Genetic 
instability and darwinian selection in tumours. Trends Cell Biol. 
1999; 9: M57‐60. 
99.  Hempen  PM,  Zhang  L,  Bansal  RK,  Iacobuzio‐Donahue  CA, 
Murphy KM, Maitra A, Vogelstein B, Whitehead RH, Markowitz 
SD, Willson JK, Yeo CJ, Hruban RH, Kern SE. Evidence of selection 













103.  Blagosklonny  MV.  Carcinogenesis,  cancer  therapy  and 
chemoprevention. Cell Death Differ. 2005; 12: 592‐602. 
104.  Dotto  GP,  Parada  LF,  Weinberg  RA.  Specific  growth 
response  of  ras‐transformed  embryo  fibroblasts  to  tumour 
promoters. Nature. 1985; 318: 472‐475. 
105.  Blagosklonny  MV.  Antiangiogenic  therapy  and  tumor 
progression. Cancer Cell. 2004; 5: 13‐17. 
106.  Blagosklonny  MV.  Why  therapeutic  response  may  not 
prolong  the  life  of  a  cancer  patient:  selection  for  oncogenic 
resistance. Cell Cycle. 2005; 4: 1693‐1698. 
107. Fleenor CJ, Marusyk A, DeGregori J. Ionizing radiation and 
hematopoietic  malignancies:  altering  the  adaptive  landscape. 
Cell Cycle. 2010; 9: 3005‐3011. 
108. Aziz MH, Shen H, Maki CG. Acquisition of p53 mutations in 
response  to  the  non‐genotoxic  p53  activator  Nutlin‐3. 
Oncogene. 2011; 30: 4678‐4686. 
109.  Uemura  N,  Okamoto  S,  Yamamoto  S,  Matsumura  N, 
Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. 








immunity,  inflammation,  and  cancer.  J  Clin  Invest.  2007;  117: 
1175‐1183. 
113. Porta C, Subhra Kumar B, Larghi P, Rubino L, Mancino A, 























www.impactaging.com                 1136                                  AGING,  December 2011, Vol.3 No.12the  tumor  microenvironment:  connecting  aging,  inflammation 
and cancer metabolism with personalized medicine. Cell Cycle. 
2011; 10: 2059‐2063. 
121.  Balliet  RM,  Capparelli  C,  Guido  C,  Pestell  TG,  Martinez‐
Outschoorn UE, Lin Z, Whitaker‐Menezes D, Chiavarina B, Pestell 
RG, Howell A, Sotgia F, Lisanti MP. Mitochondrial oxidative stress 
in  cancer‐associated  fibroblasts  drives  lactate  production, 
promoting  breast  cancer  tumor  growth:  Understanding  the 
aging and cancer connection. Cell Cycle. 2011; 10: 4065‐4073. 
122.  Krtolica  A,  Campisi  J.  Integrating  epithelial  cancer,  aging 
stroma and cellular senescence. Adv Gerontol. 2003; 11: 109‐
116. 




Escudero  E,  Jimenez  R,  Cenador  MB,  Criado  FJ,  Cobaleda  C, 
Sanchez‐Garcia  I.  The  age  of  the  target  cell  affects  B‐cell 
leukaemia malignancy. Aging. 2010; 2: 908‐913. 
125. Henry CJ, Marusyk A, Zaberezhnyy V, Adane B, DeGregori J. 







Reversing  the  aging  stromal  phenotype  prevents  carcinoma 
initiation. Aging. 2011; 3: 407‐416. 
128.  Campisi  J,  Andersen  JK,  Kapahi  P,  Melov  S.  Cellular 
senescence: A link between cancer and age‐related degenerative 
disease? Semin Cancer Biol. 2011; 21: 354‐359. 
129.  Hursting  SD,  Perkins  SN,  Phang  JM.  Calorie  restriction 









deCabo  R.  Calorie  restriction  mimetics:  an  emerging  research 
field. Aging Cell. 2006; 5: 97‐108. 
133.  Ingram  DK,  Anson  RM,  de  Cabo  R,  Mamczarz  J,  Zhu  M, 







135.  Longo  VD,  Fontana  L.  Calorie  restriction  and  cancer 
prevention:  metabolic  and  molecular  mechanisms.  Trends 
Pharmacol Sci. 2010; 31: 89‐98. 
136.  Fontana  L,  Partridge  L,  Longo  VD.  Extending  healthy  life 
span‐‐from yeast to humans. Science. 2010; 328: 321‐326. 
137. Blagosklonny MV. Calorie restriction: Decelerating mTOR‐










Semenchenko  AV,  Tyndyk  ML,  Yurova  MN,  Antoch  MP, 
Blagosklonny  MV.  Rapamycin  extends  maximal  lifespan  in 
cancer‐prone mice. Am J Pathol. 2010; 176: 2092‐2097. 
141. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, 
Semenchenko  AV,  Tyndyk  ML,  Yurova  MN,  Blagosklonny  MV. 
Rapamycin  increases  lifespan  and  inhibits  spontaneous 
tumorigenesis in inbred female mice. Cell Cycle. 2011; 10. 
142. Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J. 
Senescent  fibroblasts  promote  epithelial  cell  growth  and 
tumorigenesis: a link between cancer and aging. Proc Natl Acad 
Sci U S A. 2001; 98: 12072‐12077. 




Nelson  PS,  Desprez  PY,  Campisi  J.  Senescence‐associated 





DNA  damage  signalling  triggers  senescence‐associated 
inflammatory cytokine secretion. Nat Cell Biol. 2009; 11: 973‐
979. 










150.  Chauncey  SS,  Boothman  DA,  Habib  AA.  The  receptor 





152.  Donato  AJ,  Pierce  GL,  Lesniewski  LA,  Seals  DR.  Role  of 
NFkappaB  in  age‐related  vascular  endothelial  dysfunction  in 
humans. Aging. 2009; 1: 678‐680. 
153.  Demchenko  YN,  Kuehl  WM.  A  critical  role  for  the  NFkB 
pathway in multiple myeloma. Oncotarget. 2010; 1: 59‐68. 
















resistance,  and  cell  survival  deficiencies.  Curr  Biol.  2004;  14: 
1650‐1656. 
159.  Zhang  H,  Bajraszewski  N,  Wu  E,  Wang  H,  Moseman  AP, 
Dabora  SL,  Griffin  JD,  Kwiatkowski  DJ.  PDGFRs  are  critical  for 









162.  Castilho  RM,  Squarize  CH,  Chodosh  LA,  Williams  BO, 






suppressors  that  inhibit  leukemogenesis  and  deplete 







166.  Shaw  RJ,  Cantley  LC.  Ras,  PI(3)K  and  mTOR  signalling 
controls tumour cell growth. Nature. 2006; 441: 424‐430. 
167.  Janes  MR,  Fruman  DA.  Targeting  TOR  dependence  in 
cancer. Oncotarget. 2010; 1: 69‐76. 
168.  Markman  B,  Dienstmann  R,  Tabernero  J.  Targeting  the 
PI3K/Akt/mTOR pathway‐‐beyond rapalogs. Oncotarget. 2010; 1: 
530‐543. 
169.  Cully  M,  You  H,  Levine  AJ,  Mak  TW.  Beyond  PTEN 
mutations: the PI3K pathway as an integrator of multiple inputs 
during tumorigenesis. Nat Rev Cancer. 2006; 6: 184‐192. 











174.  Martelli  AM,  Evangelisti  C,  Chiarini  F,  McCubrey  JA.  The 
phosphatidylinositol 3‐kinase/Akt/mTOR signaling network as a 
therapeutic  target  in  acute  myelogenous  leukemia  patients. 
Oncotarget. 2010; 1: 89‐103. 
175.  Nucera  C,  Lawler  J,  Hodin  R,  Parangi  S.  The  BRAFV600E 
mutation:  what  is  it  really  orchestrating  in  thyroid  cancer? 
Oncotarget. 2010; 1: 751‐756. 
176.  Zawel  L.  P3Kalpha:  a  driver  of  tumor  metastasis? 
Oncotarget. 2010; 1: 315‐316. 
177.  Zhang  Z,  Stiegler  AL,  Boggon  TJ,  Kobayashi  S,  Halmos  B. 
EGFR‐mutated lung cancer: a paradigm of molecular oncology. 
Oncotarget. 2010; 1: 497‐514. 
178.  Shahbazian  D,  Parsyan  A,  Petroulakis  E,  Hershey  J, 
Sonenberg  N.  eIF4B  controls  survival  and  proliferation  and  is 





180.  Fujishita  T,  Aoki  M,  Taketo  MM.  The  role  of  mTORC1 
pathway in intestinal tumorigenesis. Cell Cycle. 2009; 8: 3684‐
3687. 
181.  Roux  PP,  Ballif  BA,  Anjum  R,  Gygi  SP,  Blenis  J.  Tumor‐
promoting  phorbol  esters  and  activated  Ras  inactivate  the 
tuberous sclerosis tumor suppressor complex via p90 ribosomal 
S6 kinase. Proc Natl Acad Sci U S A. 2004; 101: 13489‐13494. 
182.  De  La  OJ,  Murtaugh  LC.  Notch  and  Kras  in  pancreatic 




Ittmann  M,  Tycko  B,  Hibshoosh  H,  Wigler  MH  et  al.  PTEN,  a 
putative protein tyrosine phosphatase gene mutated in human 
brain,  breast,  and  prostate  cancer.  Science.  1997;  275:  1943‐
1947. 
184. Di Cristofano A, Pesce B, Cordon‐Cardo C, Pandolfi PP. Pten 




implications  for  tuberous  sclerosis  and  cancer  pathogenesis. 
Cell. 2005; 121: 179‐193. 
186.  Jones  RG,  Thompson  CB.  Tumor  suppressors  and  cell 
metabolism: a recipe for cancer growth. Genes Dev. 2009; 23: 
537‐548. 
187.  Shackelford  DB,  Shaw  RJ.  The  LKB1‐AMPK  pathway: 
metabolism and growth control in tumour suppression. Nat Rev 
Cancer. 2009; 9: 563‐575. 






Tamburini  J.  LKB1/AMPK/mTOR  signaling  pathway  in 











www.impactaging.com                 1138                                   AGING, December 2011, Vol.3 No.12194. Feng Z, Hu W, de Stanchina E, Teresky AK, Jin S, Lowe S, 
Levine  AJ.  The  regulation  of  AMPK  beta1,  TSC2,  and  PTEN 
expression by p53: stress, cell and tissue specificity, and the role 






communication  between  the  p53  and  IGF‐1‐AKT‐TOR  signal 
transduction pathways. Genes Dev. 2006; 20: 267‐275. 
197.  Budanov  AV,  Karin  M.  p53  target  genes  sestrin1  and 





















biology  of  cancer:  metabolic  reprogramming  fuels  cell  growth 
and proliferation. Cell Metab. 2008; 7: 11‐20. 
206.  Demidenko  ZN,  Blagosklonny  MV.  Quantifying 
pharmacologic suppression of cellular senescence: prevention of 
cellular  hypertrophy  versus  preservation  of  proliferative 
potential. Aging. 2009; 1: 1008‐1016. 
207. Demidenko ZN, Blagosklonny MV. The purpose of the HIF‐




Inoki  K,  Shimizu  S.  Spatial  coupling  of  mTOR  and  autophagy 
augments secretory phenotypes. Science. 2011; 332: 966‐970. 
209.  Medema  RH,  Herrera  RE,  Lam  F,  Weinberg  RA.  Growth 
suppression  by  p16ink4  requires  functional  retinoblastoma 
protein. Proc natl Acad Sci USA. 1995; 92: 62289‐66293. 
210. de Jonge HJ, Woolthuis CM, de Bont ES, Huls G. Paradoxical 













causes  Rb‐dependent  cell  cycle  arrest  and  senescence  in 
prostate cancer cells. Oncotarget. 2010; 1: 349‐358. 
215.  Akakura  S,  Nochajski  P,  Gao  L,  Sotomayor  P,  Matsui  S, 
Gelman IH. Rb‐dependent cellular senescence, multinucleation 




association  with  disease  subtypes,  disease‐specific  prognosis 
and therapeutic response. Cell Cycle. 2010; 9: 4153‐4163. 
217. Land H, Parada LF, Weinberg RA. Tumorigenic conversion of 
primary  embryo  fibroblasts  requires  at  least  two  cooperating 
oncogenes. Nature. 1983; 304: 596‐602. 
218. Kauffmann‐Zeh A, Rodriguez‐Viciana P, Ulrich E, Gilbert C, 
Coffer  P,  Downward  J,  Evan  G.  Suppression  of  c‐Myc‐induced 
apoptosis  by  Ras  signalling  through  PI(3)K  and  PKB.  Nature. 
1997; 385: 544‐548. 
219.  Serrano  M,  Lin  AW,  McCurrach  ME,  Beach  D,  Lowe  SW. 
Oncogenic ras provokes premature cell senescence associated 
with accumulation of p53 and p16INK4a. Cell. 1997; 88: 593‐602. 
220.  Hueber  AO,  Evan  GI.  Traps  to  catch  unwary  oncogenes. 
Trends Genet. 1998; 14: 364‐367. 




































www.impactaging.com                 1139                                  AGING,  December 2011, Vol.3 No.12233.  Demidenko  ZN,  Zubova  SG,  Bukreeva  EI,  Pospelov  VA, 
Pospelova TV, Blagosklonny MV. Rapamycin decelerates cellular 
senescence. Cell Cycle. 2009; 8: 1888‐1895. 
234.  Demidenko  ZN,  Shtutman  M,  Blagosklonny  MV. 




inhibit  mTOR,  resveratrol  suppresses  cellular  senescence.  Cell 
Cycle. 2009; 8: 1901‐1904. 





237.  Wesierska‐Gadek  J.  mTOR  and  its  link  to  the  picture  of 





M  et  al.  Oncogene‐induced  senescence  is  part  of  the 




R,  Pelicci  PG,  d'Adda  di  Fagagna  F.  Oncogene‐induced 
senescence is a DNA damage response triggered by DNA hyper‐
replication. Nature. 2006; 444: 638‐642. 
240.  Mallette  FA,  Gaumont‐Leclerc  MF,  Ferbeyre  G.  The  DNA 
damage signaling  pathway  is  a critical  mediator  of  oncogene‐
induced senescence. Genes Dev. 2007; 21: 43‐48. 
241. Bartek J, Lukas J, Bartkova J. DNA damage response as an 
anti‐cancer  barrier:  damage  threshold  and  the  concept  of 
'conditional haploinsufficiency'. Cell Cycle. 2007; 6: 2344‐2347. 












Podsypanina  K,  Rosen  JM,  Donehower  LA,  Li  Y.  Defining  the 






247.  Longo  VD,  Lieber  MR,  Vijg  J.  Turning  anti‐ageing  genes 
against cancer. Nat Rev Mol Cell Biol. 2008; 9: 903‐910. 
248.  Toledo  LI,  Murga  M,  Gutierrez‐Martinez  P,  Soria  R, 


























DNA‐PK  occurs  in  hypoxic  cells  and  contributes  to  cellular 
adaptation to hypoxia. J Cell Sci. 2011; 124: 1943‐1951. 
257. Alexander A, Walker CL. Differential localization of ATM is 
correlated  with  activation  of  distinct  downstream  signaling 
pathways. Cell Cycle. 2010; 9: 3685‐3686. 
258.  Rodriguez‐Jimenez  FJ,  Moreno‐Manzano  V,  Mateos‐




259.  Guo  Z,  Deshpande  R,  Paull  TT.  ATM  activation  in  the 
presence of oxidative stress. Cell Cycle. 2010; 9: 4805‐4811. 
260. Cam H, Easton JB, High A, Houghton PJ. mTORC1 signaling 
under  hypoxic  conditions  is  controlled  by  ATM‐dependent 
phosphorylation of HIF‐1alpha. Mol Cell. 2010; 40: 509‐520. 
261.  Shor  B,  Gibbons  JJ,  Abraham  RT,  Yu  K.  Targeting  mTOR 
globally in cancer: thinking beyond rapamycin. Cell Cycle. 2009; 
8: 3831‐3837. 
262.  Benjamin  D,  Colombi  M,  Moroni  C,  Hall  MN.  Rapamycin 
passes the torch: a new generation of mTOR inhibitors. Nat Rev 
Drug Discov. 2011; 10: 868‐880. 
263.  Morris  JZ,  Tissenbaum  HA,  Ruvkun  G.  A 

























www.impactaging.com                  1141                                  AGING, December 2011, Vol.3 No.12